Niquette L. Hunt serves as Independent Director of the Company. Ms. Hunt brings more than 25 years of general management and commercialization experience leading consumer product and biotechnology companies. Coming out of line management in both large corporations and start-ups, Ms. Hunt has proven her ability to drive significant growth on a variety of businesses across multiple industries. Ms. Hunt founded Candesant Biomedical in 2016 to develop a novel, non-invasive treatment for those who suffer from excessive sweating. She has guided the company through product development, Series A financing and is now focused on pre commercialization efforts targeting the $2B market opportunity. Prior to Candesant, Ms. Hunt was on the executive management team that took Revance Therapeutics public raising over $250M in the IPO and follow-on financings. Ms. Hunt started her career at Procter & Gamble and Warner Lambert where she managed market leading brands such as Head and Shoulders and Lubriderm.
Niquette's mailing address filed with the SEC is C/O SOLITON, INC. 5304 ASHBROOK DRIVE, , HOUSTON, TX, 77081.
Over the last 5 years, insiders at Soliton have traded over $0 worth of Soliton stock and bought 632,904 units worth $999,992 . The most active insiders traders include Walter V Klemp, Ventures Llc Remeditex e Jonathan P. Foster. On average, Soliton executives and independent directors trade stock every 126 days with the average trade being worth of $4,763,657. The most recent stock trade was executed by Ventures Llc Remeditex on 30 June 2020, trading 120,481 units of SOLY stock currently worth $999,992.
Soliton, Inc., a medical device company, develops and commercializes products using a proprietary rapid acoustic pulse technology platform. It is developing a product for the removal of tattoos. The company was founded in 2012 and is headquartered in Houston, Texas.
Soliton executives and other stock owners filed with the SEC include: